Home MarketWockhardt Ltd.

Wockhardt Ltd. Stock Info: As on 2018-02-23 15:59:51

Nse

785.30

23.10(3.03%)
Change%
52 Week Range
530.65
22.00
1,012.00
8.00
Open767.15
Day's Range685.98 - 838.42
Value Traded (in ₹ Cr.) 150.64

Bse

785.00

21.00(2.75%)
Change %
52 Week Range
531.50
22.00
1,012.00
8.00
Open772.50
Day's Range687.60 - 840.40
Value Traded (in ₹ Cr.) 17.28

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 81,985,382.00 74.13%
Mutual Funds/UTI 3,515,670.00 3.18%
FII 5,351,040.00 4.84%
Employee 0.00 0.00%
Public 13,803,542.00 12.48%
Government 0.00 0.00%
Others 4,364,203.00 3.95%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.83
Basic EPS (Rs.) 2.97
Cash EPS 12.18
BVPerShare Excl 98.68
Operating Revenue 201.33
PBDITPerShare 16.73
Dividend 0.00
NPPerShare 2.97
Current Ratio 1.52
Quick Ratio 1.10
PriceToBV 9.86
Earnings 0.00
PBDIT Margin 8.31
PBT Margin 0.14
NP Margin 1.47
Return On Assets 0.70
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,281.05
Total Expenses 2,277.84
EBITDA 184.91
PBT 3.21
PAT 32.79
Net Income 32.79
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,177.86
Total Expenses 1,063.80
EBITDA 62.33
PBT 62.12
PAT 96.85
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 353.80
Net worth 1,687.53
Investments 297.22
Total Liability 4,641.03
Total debt 1,417.76
Net block 1,973.06
Total Assets 4,641.03
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 353.80
Net worth 1,388.98
Investments 297.22
Total Liability 4,641.03
Total debt 1,716.31
Net block 1,973.06
Total Assets 4,641.03
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

613.15 607 1.01
603.6668.8

Abbott India Ltd.

5811.3 5754.4 0.99
5470.056125

Ajanta Pharma Ltd.

1374.45 1350.3 1.79
1311.31420

Albert David Ltd.

365.1 365.2 -0.03
357.4395.35

Alembic Ltd.

61.1 60.8 0.49
60.363.45

Alembic Pharmaceuticals Ltd.

561.9 563.7 -0.32
546.8585

Alkem Laboratories Ltd.

2181.3 2174.8 0.3
2115.12185
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

50.1 49.35 1.52
48.7554.15

Aarti Drugs Ltd.

608.05 607.05 0.16
602.6680

Aayush Food & Herbs Ltd.

63.6 63.5 0.16
59.166.9

Abbott India Ltd.

5788.4 5746.8 0.72
5445.355950

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities -363.18
Cash from investing activities -1,015.33
Cash from financing activities 763.89
Net change in cash -614.39

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Aditya Birla Sun Life Pure Value Fund 1.52%
ICICI Prudential Equity - Arbitrage Fund 0.20%
Aditya Birla Sun Life Enhanced Arbitrage Fund 0.36%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.10%
HDFC Arbitrage Fund - Regular Plan 0.42%
HDFC Arbitrage Fund - Wholesale Plan 0.42%

ABC India posts Q3 net loss of Rs 2.25 cr

The company reported standalone net loss during the quarter stood at Rs 2.25 crore as compared to net loss of Rs 13.70 crore in the previous year quarter. Net revenue of the company declined moderately by 12.76 per cent at Rs 28.45 crore in October-December quarter of this fiscal as against Rs 32.61 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 33.09 per cent to Rs 29.90 crore from Rs 44.69 crore in year ago period. Other Income grew by 400.00 per cent at Rs 0.05 crore versus (Dec'16 Rs 0.01 crore). Operating Profit slipped by 87.88 per cent to Rs -1.46 crore as against Rs -12.05 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 86.14 per cent in December quarter. Interest declined by 10.78 per cent y-o-y to Rs 0.91 crore, while Taxation decreased by 40.00 per cent at Rs -0.03 crore (Dec'16 Rs -0.05 crore).

23-02-2018 15:37

Zenith Exports L posts Q3 net loss of Rs 1.49 cr

The company reported standalone net loss during the quarter stood at Rs 1.49 crore compared to net profit of Rs 0.51 crore in the previous year quarter. Net revenue of the company declined moderately by 17.19 per cent at Rs 21.87 crore in October-December quarter of this fiscal as against Rs 26.41 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 19.87 per cent to Rs 22.46 crore from Rs 28.03 crore in year ago period. Other Income dipped by 14.81 per cent at Rs 0.23 crore versus (Dec'16 Rs 0.27 crore). Operating Profit slipped by 171.95 per cent to Rs -0.59 crore as against Rs 0.82 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 187.10 per cent in December quarter. Interest grew by 320.00 per cent y-o-y to Rs 0.21 crore, while Taxation increased by 42.86 per cent at Rs 0.30 crore (Dec'16 Rs 0.21 crore).

23-02-2018 15:37

Austin Engg. Co. posts Q3 net loss of Rs 0.70 cr

The company reported standalone net loss during the quarter stood at Rs 0.70 crore as compared to net loss of Rs 0.83 crore in the previous year quarter. Net revenue of the company declined moderately by 9.59 per cent at Rs 16.02 crore in October-December quarter of this fiscal as against Rs 17.72 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 11.67 per cent to Rs 16.42 crore from Rs 18.59 crore in year ago period. Other Income dipped by 92.00 per cent at Rs 0.02 crore versus (Dec'16 Rs 0.25 crore). Operating Profit slipped by 40.00 per cent to Rs -0.39 crore as against Rs -0.65 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 33.60 per cent in December quarter. Interest declined by 33.33 per cent y-o-y to Rs 0.14 crore, while Taxation increased by 25.00 per cent at Rs -0.10 crore (Dec'16 Rs -0.08 crore).

23-02-2018 15:37

Dhoot Industrial Q3 net profit zooms 264.91% at Rs 2.08 cr

The company reported standalone net profit of Rs 2.08 crore for the quarter ended December 31, 2017 as compared to Rs 0.57 crore in the same period last year, registering a year-on-year growth of 264.91 per cent. Net revenue of the company rose moderately by 8.18 per cent at Rs 18.25 crore in October-December quarter of this fiscal as against Rs 16.87 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 5.41 per cent to Rs 16.26 crore from Rs 17.19 crore in year ago period. Other Income grew by 6.71 per cent at Rs 1.75 crore versus (Dec'16 Rs 1.64 crore). Operating Profit surged by 123.60 per cent to Rs 1.99 crore as against Rs 0.89 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 107.62 per cent in December quarter. Interest declined by 38.46 per cent y-o-y to Rs 0.64 crore, while Taxation increased by 18.31 per cent at Rs 0.84 crore (Dec'16 Rs 0.71 crore).

23-02-2018 15:37

ITL Industries Q3 net profit jumps 65.85% at Rs 1.36 cr

The company reported standalone net profit of Rs 1.36 crore for the quarter ended December 31, 2017 as compared to Rs 0.82 crore in the same period last year, registering a year-on-year growth of 65.85 per cent. Net revenue of the company rose moderately by 16.94 per cent at Rs 20.30 crore in October-December quarter of this fiscal as against Rs 17.36 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 17.41 per cent to Rs 18.34 crore from Rs 15.62 crore in year ago period. Other Income grew by 1600.00 per cent at Rs 0.17 crore versus (Dec'16 Rs 0.01 crore). Operating Profit surged by 12.64 per cent to Rs 1.96 crore as against Rs 1.74 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 3.50 per cent in December quarter. Interest declined by 49.02 per cent y-o-y to Rs 0.26 crore, while Taxation increased by 100.00 per cent at Rs 0.28 crore (Dec'16 Rs 0.14 crore).

23-02-2018 15:37

Wockhardt Ltd. - Reply to Clarification Sought

WOCKPHARMA:The Exchange has sought clarification from Wockhardt Limited with respect to announcement dated 15-Feb-2018, regarding Wockhardt Limited has informed the Exchange regarding Credit Rating: CARE Ratings Limited (CARE Ratings) has revised the Company''s Rating for Long - Term Bank Facilities (Fund Based Working Capital limit) as CARE A+; Outlook: Stable from earlier it was CARE AA-; Outlook: Negative and Short Term Bank Facilities (Non Fund Based Working Capital limit) as CARE A1 from CARE A1+. Further, CARE Ratings has also revised rating for the proposed issue of NCDs for an amount of Rs. 250 crore of the Company as CARE A+; Outlook: Stable from earlier it was CARE AA-; Outlook: Negative.. On basis of above the Company is required to clarify following: 1. In case of downward rating, the disclosure may include reasons published by rating agency for such downward rating.The response of the Company is attached.

20-Feb-2018 06:58 PM

Wockhardt Ltd. - Announcement under Regulation 30 (LODR)-Updates

Clarification on the disclosure submitted by the Company on 15th February, 2018.

20-Feb-2018 12:55 PM

Wockhardt Ltd. - Updates

Wockhardt Limited has informed the Exchange regarding ''Clarification on the disclosure submitted earlier.''.

20-Feb-2018 12:50 PM

Wockhardt Ltd. - Clarification

WOCKPHARMA:The Exchange has sought clarification from Wockhardt Limited with respect to announcement dated 15-Feb-2018, regarding Wockhardt Limited has informed the Exchange regarding Credit Rating: CARE Ratings Limited (CARE Ratings) has revised the Company?s Rating for Long - Term Bank Facilities (Fund Based Working Capital limit) as ?CARE A+; Outlook: Stable? from earlier it was ?CARE AA-; Outlook: Negative? and Short Term Bank Facilities (Non Fund Based Working Capital limit) as ?CARE A1? from ?CARE A1+?. Further, CARE Ratings has also revised rating for the proposed issue of NCDs for an amount of Rs. 250 crore of the Company as ?CARE A+; Outlook: Stable? from earlier it was ?CARE AA-; Outlook: Negative?.. On basis of above the Company is required to clarify following: 1. In case of downward rating, the disclosure may include reasons published by rating agency for such downward rating.The response of the Company is awaited.

19-Feb-2018 02:59 PM

Wockhardt Ltd. - Allotment of ESOP/ESPS

Wockhardt Limited has informed the Exchange regarding allotment of 33625 Equity Shares under ESOP .This disclosure is uploaded once again as the previous pdf file uploaded was not in searchable format. There is no change in the remaining text of the letter.

16-Feb-2018 06:29 PM

Wockhardt Ltd. - Announcement under Regulation 30 (LODR)-Updates

Clarification on the disclosure submitted by the Company on 15th February, 2018.

20-Feb-2018 12:55 PM

Wockhardt Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of Equity Shares pursuant to exercise of Stock Options under Employees Stock Options Scheme 2011 of the Company.

This disclosure is uploaded once again as the previous pdf file uploaded was not in searchable format. There is no change in the remaining text of the letter.

16-Feb-2018 06:28 PM

Wockhardt Ltd. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of Equity Shares pursuant to exercise of Stock Options under Employee Stock Options Scheme 2011 of the Company.

16-Feb-2018 04:15 PM

Corporate Details

About Management

YEAR EVENTS 2000 - Wockhardt has launched cardiac drug enalapril maleate in the US through its marketing joint venture with Sidmak Laboratories. - Pharmaceutical major Wockhardt Ltd has set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad. 2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of Wockhardt Ltd, will set up two cardiac hospitals in Mumbai and Bangalore. - The Company has terminated its three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic pharma companies in the US. - Pharma major Wockhardt Ltd. has entered into a strategic alliance with a Japanese firm Eisai Company Ltd. to manufacture and market a neurology drug -- Methycobal. - Wockhardt Hospitals Ltd, the wholly owned subsidiary of pharmaceutical major Wockhardt Ltd, has tied up with four international health insurance companies to offer medical cover to non-resident Indians. - AGM JUNE 8 2001 Wockhardt has launched an innovative and attractive employee stock option scheme, ESOP. - Wockhardt Ltd has introduced an employee stock option (ESOP) scheme for over 175 employees in the senior and middle management levels with about 2,00,000 shares being allotted. 2002 -The Hari L Mundra has joined Wockhardt as vice-chairman. Mundra will spearhead the company's domestic operations which account for 70 per cent of its turnover. - Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director on its Corporate Board. Mr. Kumar will spearhead Wockhardt's International Business covering bulk drug operations and formulations export, as well as ANDA research and Intellectual Property Rights. 2003 -Wockhardt restructured its field organization to upgrade its competitiveness and productivity. -Mumbai based wockhardt will hit the domestic market with the first indigenously developed insulin soon, in a move to induce turmoil in the market. -Wockhardt has launched new four speciality hospitals at its Mulund complex in Mumbai. -Maharashtra Government decided to terminate its Joint Venture agreement with Wockhardt for setting up a super speciality hospital. -Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd, along with its subsidiaries. -Wockhardt is strengthening its marketing strategies and distribution system to unveil human insulin in Indian market. -Wockhardt Launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product. -Wockhardt Ltd has received USFDA approval for marketing bethanecol Chloride tablets in the US. -Wockhardt baged USFDA approval for Bethanechol -Baged US approval to sell bethanechol chloride tablets -Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on the board of the company as Executive Director, has resigned from the directorship with immediate effect. 2004 -Wockhardt Ltd has filed an Investigational New Drug (IND) application for its new drug for respiratory infections, WCK-1152 - Wockhardt Ltd has acquired German pharmaceutical company esparma GmbH for a consideration of $11 million (around Rs 49 crore). -Centre for Drug Evaluation & Research, an arm of the US Food & Drug Administration (US FDA), has approved the sterile injectable facility as well as facilities for sterile bulk drugs (active pharmaceutical ingredient) and formulations spread over three locations in India -Wockhardt gets USFDA nod for 6 manufacturing units 2005 -Launches of India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients on February 14, 2005 -Wockhardt forges alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad -Wockhardt unveils father`s heart network -Wockhardt receives US FDA approval for marketing cefuroxime axetil in the US market -Wockhardt unveils new generation hepatitis A vaccine -Wockhardt rolls out new Hepatitis A vaccine 2006 -Wockhardt's Waluj plant approved by US FDA 2007 -Wockhardt signs in-licensing pact with Crawford Healthcare of UK. -Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance & Information for a period of five years effective from February 22, 2007, subject to the approval of shareholders. -Wockhardt Ltd has announced US FDA approval for marketing Ketorolac anti-inflammatory injection in the US market, its third US FDA approval in the last ten days. - Wockhardt Ltd on May 03, 2007 has announced the acquisition of Negma Laboratories, the fourth largest independent, integrated pharmaceutical group in France with sales of $ 150 million. The Company has acquired Negma Laboratories in an all-cash deal worth $ 265 million. The transaction is valued at 1.8 times the sales and 9.7 times the EBITDA. 2008 Wockhardt Ltd has unveiled Cetirizine tablets in the US, after having got the regulatory clearance to market different strengths of anti-allergy medicine Cetirizine Hydrochloride. Cetirizine is the generic version of Pfizer's Zyrtec brand and the total market for Cetirizine tablets in the US is $1.4 billion. - Wockhardt Ltd has forayed into a 10- year in-licensing pact with the UK's Sinclair Pharma plc to market dermatology and dental products in India. 2009 -A biotechnology breakthrough in Diabetes Wockhardt launches new insulin (Glaritus) in India. -Harvard Medical School Professor shows connection of Cancer and Heart diseases with Diabetes. -Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala. -Wockhardt launches anti-hypertensive drug Nicardipine injections in USA. -Wockhardt wins Government of India Patent Award. -Wockhardt appoints BDO Haribhakti as auditor. -Wockhardt announces Entacapone patent settlement with Orion Corporation. 2010 -Wockhardt receives US FDA approval for antibacterial Levofloxacin -Wockhardt launches Prostate drug Flomax in the United States on Day-1. -Wockhardt receives US FDA approval for the generic version of Toprol XLr, a cardiac drug. 2011 -Wockhardt launches generic version of Protonixr tablets in the US. -Wockhardt receives US FDA approval for generic version of Effexor XRr capsules. -Wockhardt launches three new products in three weeks, in the United States. -Wockhardt receives tentative US FDA approval for generic version of Patanolr ophthalmic solution. 2012 -Wockhardt launches generic version of anti--ulcer drug Prevacidr. -Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XLr. -Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodonr. -Wockhardt receives US FDA approval for generic version of Parkinson's drug Comtanr. 2013 -Wockhardt receives the 'Best Enterprise' award from the Europe. -Wockhardt launches generic version of anti-convulsant drug Lamictal XR. 2014 -Wockhardt's drug discovery gets a boost with fast track approval by USFDA. 2015 -Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt 2015 -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -Wockhardt receives ANDA approval for pain medication Oxycodone liquid -Wockhardt gains over 2% after MHRA completes plant inspection -Wockhardt gets QIDP status for new antibiotic from US FDA.

Registered Office

PO Barotiwala,

01795-664444,,,      01795-664312,

Registrar Details

Link Intime India Pvt. Ltd.